• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals (‘AFT’) has reached agreement with privately-owned Swiss headquartered multinational pharmaceutical company, Acino Pharma AG (‘Acino’), to out-license the product line of its patented combination painkiller, Maxigesic, to a further 69 countries.

    To view the announcements please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Analyst Coverage

Firm Analyst Contact Details Reports
First NZ Capital/Credit Suisse Greg Main Direct line: +64 4 474 4061
Mobile: +64 21 937 271
Fax: +64 4 496 5311
Email: greg.main@fnzc.co.nzOpens in new window
Website: www.firstnzcapital.co.nzOpens in new window
Edison Group Maxim Jacobs

Dennis Hulme
Telephone: +1 646 653 7027
Email: mjacobs@edisongroup.comOpens in new window

Telephone: +61 (0)2 8211 0429
Email: DHulme@edisongroup.comOpens in new window

Website: www.edisongroup.comOpens in new window